Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × ESCC × camrelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 20 Carcinoma, Hepatocellular 19 Triple Negative Breast Neoplasms 11 Esophageal Squamous Cell Carcinoma 10 Esophageal Neoplasms 10 Stomach Neoplasms 9 Nasopharyngeal Carcinoma 9 Squamous Cell Carcinoma of Head and Neck 5 Melanoma 5 Uterine Cervical Neoplasms 4 Sarcoma 4 Recurrence 4 Lung Neoplasms 4 Hodgkin Disease 4 Colorectal Neoplasms 4 Breast Neoplasms 4 Small Cell Lung Carcinoma 3 Neoplasm Metastasis 3 Advanced Gastric Cancer 3 Rectal Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Neoplasms 2 NSCLC 2 Metastatic Gastric Adenocarcinoma 2 Lymphoma, Extranodal NK-T-Cell 2 Locally Advanced Gastric Cancer 2 Liver Neoplasms 2 Head and Neck Neoplasms 2

Interventions

camrelizumab 1 anlotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05050760 2023-01-31

DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer

Xijing Hospital

Phase NA Unknown

ESCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡